Search

High-throughput screening (HTS) has consistently improved throughput and miniaturization since its development. Yet, despite better automation, detection technologies, target selection, and compound libraries, researchers still face many difficulties in HTS assay development. "The greater challenge in developing assays is a paradigm shift from thinking that anything done on the bench can be run on the robot to designing an assay with the robot in mind," says Peter Hodder, head of HTS robotics, Merck & Co. Inc., Whitehouse Station, New Jersey. INSET: Noncontact Picoliter Dispensing with Ultrasound.

The article reports that the clinical drug development services provider Clinilabs Inc. has opened a second Phase 1 unit in New Jersey.

The article reports on the launch of Covance Inc.'s chemistry, manufacturing, and controls (CMC) pharmaceutical development services in New Jersey.

Focuses on the career of Dennis France, executive director of the molecular feasibility unit of Novartis Oncology in New Jersey. Educational background; Views on molecular epidemiology; Overview on Novartis Oncology business. INSETS: Marine Compounds: A Natural Selection;New Novartis Institute for Biomedical Research Inc. (NIBRI).